<DOC>
	<DOCNO>NCT00323830</DOCNO>
	<brief_summary>The objective trial compare disease-free survival adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin radiotherapy ( chemoradiation ) curatively resect gastric cancer patient .</brief_summary>
	<brief_title>Phase III Randomized Trial Adjuvant XP Chemotherapy XP/RT Resected Gastric Adenocarcinoma</brief_title>
	<detailed_description>Although gastrectomy potentially curative treatment gastric cancer patient , overall survival result remain unsatisfactory . The main factor accounting high mortality rate relapse surgical resection . During past decade , principle combined modality treatment develop apply practice various solid tumor gastric cancer exception . In attempt prevent recurrence increase cure rate gastric cancer patient surgery , multiple study use variable modality undertake . One landmark study adjuvant trial Intergroup study INT-0116 , report significant improvement survival use chemoradiation therapy gastric resection stage Ib IV gastric cancer . Thereafter , chemoradiation therapy gain popularity increasingly recognize standard care U.S . Nevertheless , result INT-0116 study challenge fact surgical treatment apply trial gastrectomy limit lymph node dissection ( D0 D1 ) 90 % case . Therefore , debatable whether adjuvant chemoradiation therapy confer survival benefit patient extensive lymph node dissection . It still disputable chemoradiotherapy D2 improve result D2 alone . Thus , assessment effect adjuvant chemoradiotherapy D2 resect gastric cancer essential .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically proven gastric adenocarcinoma 2 . ≥ D2 resection 3 . Stage IB ( T1N1 , T2bN0 ) , II , IIIA , IIIB , IV ( T4 , N3 포함 , M1 lymph node 제외 ) 4 . 18 ≤ age ≤ 75 5 . ECOG 02 6 . No distant metastasis 7 . Adequate bone marrow function ( ANC ≥ 1,500/ul , blood platelet ≥ 100,000/ul , haemoglobin ≥ 10g/dl ) 8 . Adequate renal function ( serum creatinine ≤ 1.5mg/dl ) 9. liver function ( serum bilirubin ≤ 1.5mg/dl , AST/ALT ≤ 3 time ( normal value ) 10 . Written inform consent 1 . Previous history immunotherapy , chemotherapy , radiotherapy gastric cancer 2 . Active infection require antibiotic 3 . Pregnant , lactate woman 4 . Psychiatric illness , epileptic disorder 5 . Concurrent systemic illness appropriate chemotherapy 6 . Resection margin ( + ) 7 . Pathologic stage IA 8 . History malignancy within 5 year except nonmelanoma skin cancer , cervix situ carcinoma 9 . M1 lymph node ( + ) 10 . D0 , D1 resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>postoperative therapy</keyword>
	<keyword>chemotherapy</keyword>
</DOC>